⚡ Quick Start — If You Read Nothing Else

The 10 most important things to know right now.

Sarcoidosis is your immune system building tiny clusters called granulomas in one or more organs. It most often affects the lungs and the lymph nodes in the chest, but it can also involve the heart, nervous system, eyes, skin, liver, and other organs. It is not a cancer and it is not contagious.
Many people get better without any treatment. A large share of people — especially those with mild lung disease or with the acute form called Löfgren syndrome — improve on their own. Careful monitoring (“watchful waiting”) is an evidence-based choice, not “doing nothing.”
Treatment is reserved for symptoms or organ-threatening disease. The goal is to protect organ function and quality of life while avoiding medicines you do not need.
Diagnosis is a process of exclusion. Before settling on sarcoidosis, your team must rule out look-alikes — especially tuberculosis, fungal infections, a workplace exposure called chronic beryllium disease, and lymphoma.
Prednisone (a steroid) is usually the first medicine when treatment is needed — used at the lowest effective dose for the shortest time, because long-term steroids carry real side effects.
Steroid-sparing medicines like methotrexate are now used early. A 2025 clinical trial (PREDMETH) found methotrexate worked about as well as prednisone as a first treatment for lung sarcoidosis, with fewer ongoing side effects — a meaningful shift in care.
The heart deserves special attention. Heart involvement is uncommon but is one of the most dangerous forms. Palpitations, fainting or near-fainting, or new unexplained breathlessness should be reported promptly — these can be the first sign of cardiac sarcoidosis.
Fatigue is the most common and most disabling symptom — and it is real, even when scans look stable. It deserves attention in its own right.
For the minority whose lungs scar (fibrosis), an antifibrotic medicine (nintedanib) can slow decline, and advanced disease can be managed with oxygen, rehabilitation, and — when appropriate — lung transplant.
Be honest with yourself about the “cure” landscape. Promising targeted drugs have been tested, but the two most advanced recent trials (efzofitimod and namilumab) did not meet their main goals. Efzofitimod is still being developed in a redesigned phase 3, but nothing new is approved yet. That makes proven care — and good shared decision-making — more important than chasing the newest thing.

▼ Collapse

Understanding Sarcoidosis

Sarcoidosis (sar-koy-DOH-sis) is an inflammatory disease in which the immune system forms small clumps of inflammatory cells called granulomas. Under the microscope these are described as “noncaseating” granulomas, which simply means they do not have the cheesy dead center that tuberculosis granulomas typically have — a clue pathologists use to tell the two apart. Granulomas can form in almost any organ, but in more than 90% of people the lungs and the lymph nodes inside the chest are involved.

Why the immune system does this is still not fully understood. The leading idea is that in a genetically susceptible person, some trigger (perhaps an inhaled particle, a microbe, or another environmental exposure) sets off an exaggerated immune response that then does not switch off normally. Importantly, this means sarcoidosis is not something you caught from someone, did to yourself, or could have easily prevented.

The single most reassuring fact about sarcoidosis: for many people it is self-limiting. A substantial proportion of patients improve or fully remit on their own, often within 2–3 years, and never need long-term medication. The challenge is identifying the smaller group whose disease is progressive or organ-threatening — which is exactly what your specialist team is watching for.

The many faces of sarcoidosis

Because granulomas can appear in different organs, sarcoidosis looks very different from one person to the next:

Lungs and chest lymph nodes — the most common site. May cause cough, breathlessness on exertion, or chest discomfort — or no symptoms at all (often found incidentally on an X-ray).
Löfgren syndrome — an acute, dramatic-looking but generally favorable form: tender red bumps on the shins (erythema nodosum), swollen chest lymph nodes, and arthritis/fever. Most people with Löfgren syndrome recover fully.
Heart — uncommon but important; can cause rhythm problems, conduction block, or weakening of the heart muscle.
Nervous system (neurosarcoidosis) — can affect cranial nerves (e.g., facial weakness), the brain, the lining of the brain, or the spinal cord.
Eyes — inflammation inside the eye (uveitis) can threaten sight and sometimes appears before other symptoms.
Skin — ranges from erythema nodosum to a disfiguring purplish rash on the nose and cheeks called lupus pernio.
Liver, spleen, kidneys, bone marrow, muscles and joints — often silent, sometimes causing high blood calcium, kidney stones, or blood-count changes.

Ask your doctor: "Which of my organs are involved, how did you check each one, and what is the realistic range of outcomes for my pattern of disease?"

Who gets sarcoidosis?

Sarcoidosis occurs worldwide but varies by ancestry and region. It is more common — and tends to be more severe — in people of African ancestry, and it is also frequent in Northern Europe. Löfgren syndrome (the favorable acute form) is especially common in some European populations, such as Scandinavians. It most often appears between ages 20 and 60. Knowing these patterns helps your doctors anticipate risks, but your individual course is what matters most.

For lung sarcoidosis, doctors sometimes describe a chest X-ray “stage” using a system called the Scadding stages. This is a snapshot of the X-ray pattern — not a measure of how sick you are or a step-by-step progression like cancer staging:

Stage 0: normal chest X-ray.
Stage I: enlarged lymph nodes at the center of the chest (bilateral hilar lymphadenopathy), lungs clear. Often the most likely to resolve on its own.
Stage II: enlarged lymph nodes plus changes in the lung tissue.
Stage III: lung-tissue changes without the node enlargement.
Stage IV: scarring (fibrosis).

People can move between stages, stay the same for years, or improve. A “higher” number is associated with a somewhat lower chance of spontaneous resolution but does not dictate your future on its own.

What is sarcoidosis, and why is my immune system forming granulomas?
Which of my organs are involved, and how do you know?
Is my disease the acute kind (like Löfgren syndrome) that often gets better on its own, or a more chronic form?
What is my chest X-ray “stage,” and what does that mean for me specifically?
What is the realistic range of outcomes for someone with my pattern of disease?
Who will be on my care team, and which specialist coordinates everything?

For caregivers: Sarcoidosis is often an invisible illness — your person may look well while feeling exhausted or short of breath. One of the most valuable things you can do early is help keep an organized record: which organs are involved, which specialists are seeing them, what medicines they take, and what symptoms come and go. A simple shared note or folder pays off at every appointment.

How Sarcoidosis Is Diagnosed & When Treatment Is (and Isn’t) Needed

There is no single blood test that proves sarcoidosis. Instead, the diagnosis rests on three things coming together: (1) a clinical and imaging picture that fits, (2) a tissue sample (biopsy) showing noncaseating granulomas, and (3) the careful exclusion of other conditions that can look identical. Because of that third point, doctors call sarcoidosis a diagnosis of exclusion.

Why “ruling things out” matters so much. Tuberculosis and certain fungal infections form granulomas too — and treating those with immune-suppressing sarcoidosis medicines could be dangerous. So your team will work to exclude infection (and sometimes lymphoma or a beryllium exposure) before committing to the diagnosis and to treatment. This is a feature of good care, not unnecessary delay.

Do I need a biopsy?

Often yes — but not always. When a tissue sample is needed, the most common modern approach is a minimally invasive procedure called EBUS-TBNA (endobronchial ultrasound with a needle), in which a pulmonologist passes a thin scope into the airway and uses ultrasound to guide a tiny needle into chest lymph nodes. It is generally well tolerated and has a high success rate for finding granulomas.

There are important exceptions. If you have a classic presentation — especially Löfgren syndrome (erythema nodosum + symmetric chest node enlargement + arthritis/fever) — guidelines say a biopsy is often not required, because the picture is distinctive enough on its own.

What other tests to expect at diagnosis

Because sarcoidosis can be quietly active in organs you cannot feel, an initial “organ survey” is standard. Expect some combination of:

Breathing tests (pulmonary function tests) and a chest X-ray or CT scan.
An ECG (heart tracing) as a baseline screen for heart involvement — simple and important.
An eye exam to screen for uveitis, even if your eyes feel fine.
Blood tests including calcium (sarcoidosis can raise it), kidney and liver panels, and blood counts.

Ask your doctor: "What did you rule out before settling on sarcoidosis — tuberculosis, fungal infection, beryllium exposure, and lymphoma — and how confident are you?"

Ask your doctor: "Have we done the baseline organ survey the ATS 2020 guideline recommends — breathing tests, chest imaging, an ECG, an eye exam, and a calcium level?"

You may hear about a blood test called serum ACE (angiotensin-converting enzyme). It is frequently ordered, but it is not reliable enough to diagnose sarcoidosis or to track it precisely — many people with sarcoidosis have normal ACE, and other conditions can raise it. Treat it as one small piece of the puzzle, not the answer.

When is treatment needed — and when is watching the right move?

This is one of the most counterintuitive and important ideas in sarcoidosis care: not treating is frequently the correct, evidence-based decision. Because so many people improve spontaneously, medicines are generally reserved for:

Bothersome symptoms that affect daily life (e.g., significant cough or breathlessness), or
Organ-threatening disease — involvement of the heart, nervous system, eyes, kidneys, or progressive lung disease — where damage could be permanent.

If your disease is mild and not threatening any organ, your team may recommend active monitoring: periodic symptom checks, breathing tests, blood work (including calcium), and imaging. The plan is to step in if things change — and to spare you medication side effects in the meantime.

Sarcoidosis care follows a rough timeline. Use this as a checklist to bring to appointments; your team sets the exact schedule.

First 48 hours — safety triage. Make sure any red-flag symptoms (palpitations, fainting or near-fainting, new breathlessness, vision change, new neurologic symptoms) have been reported — these can signal heart, eye, or nerve involvement and should not wait.
Within two weeks — organ survey. Confirm the baseline screen recommended for everyone is done or scheduled: breathing tests and chest imaging, an ECG to screen the heart, an eye exam for uveitis, and blood work including calcium (ATS 2020 baseline screen).
By month 1 — treat-versus-observe decision. With the organ survey back, agree on whether this is a monitor-only plan (a defined trial period of watchful waiting) or whether treatment is needed for symptoms or organ-threatening disease.
By month 3 — response check and steroid taper. If you started prednisone, this is the usual point to reassess and begin tapering toward the lowest effective dose, and to decide whether a steroid-sparing medicine should come on board.
By month 6 — steroid-sparing transition and monitoring. If more than 10 mg/day of prednisone is still needed, guidelines favor adding methotrexate (or another steroid-sparing agent) and continuing periodic blood-test monitoring rather than staying on high-dose steroids (BTS 2021).

Ask your doctor: "Is my sarcoidosis active enough to need treatment now, or is monitoring the safer choice for me — and exactly what would change that?"

Ask your doctor: "Have we screened my heart, eyes, and nervous system, and how often should each of those be re-checked?"

For caregivers: “Watchful waiting” can feel unsettling — like the doctors aren’t doing anything. It helps to reframe it: monitoring is the treatment plan for mild disease, and its whole purpose is to catch trouble early while avoiding harm. Help your person keep monitoring appointments and breathing tests, and flag new or worsening symptoms between visits.

Heart: palpitations (a racing, pounding, or skipping heartbeat), fainting or near-fainting, or new unexplained shortness of breath. Do not wait on these.
Eyes: eye redness, pain, light sensitivity, floaters, or any change in vision — uveitis can threaten sight and needs prompt care.
Lungs: a cough or breathlessness that is new, worsening, or not improving.
Nervous system: new facial weakness or droop, double vision, severe headache, numbness/tingling, or weakness.
General: profound fatigue with enlarged lymph nodes, unexplained weight loss, or drenching night sweats (the last two also warrant ruling out infection and lymphoma).

How confident are you in the diagnosis, and what other conditions did you rule out (TB, fungal infection, beryllium exposure, lymphoma)?
Did I need a biopsy, and if so, what did it show? If not, why was one not necessary?
Have we screened my heart (ECG) and eyes, and checked my calcium?
Do I need treatment now, or is monitoring the right choice for me? What would change that decision?
If we monitor, exactly which tests will we repeat, and how often?
What symptoms should make me call you sooner rather than wait for the next visit?

Steroids, Steroid-Sparing Medicines & Biologics

When treatment is needed, doctors think in terms of a flexible “ladder” — starting with what is most likely to help quickly and adding or switching agents to control disease while minimizing side effects. The ladder is not rigid; your team tailors it to which organs are involved and how you respond.

Step 1 — Glucocorticoids (prednisone)

Prednisone is the usual first medicine when treatment is indicated. It works reliably and relatively quickly to calm granulomatous inflammation. The catch is that prolonged steroid use causes real, cumulative side effects — weight gain, mood and sleep changes, higher blood sugar and blood pressure, bone thinning, cataracts/glaucoma, and infection risk. So the modern philosophy is: use the lowest dose that works, for the shortest time, and have a plan to taper.

A 2025 practice shift worth knowing. A randomized trial called PREDMETH (published in the New England Journal of Medicine) compared starting with methotrexate versus prednisone as the first treatment for pulmonary sarcoidosis. Over 24 weeks, methotrexate was about as effective at preserving lung function, with fewer side effects lingering at the end — though it works more slowly. For some people, starting with a steroid-sparing medicine instead of (or alongside a short course of) prednisone is now a reasonable, evidence-supported option to discuss.

Step 2 — Steroid-sparing medicines

These medicines let you control disease on a lower steroid dose — or sometimes no steroid. They generally act more slowly than prednisone (weeks to a few months), so they are often started while a steroid is still on board, then the steroid is tapered down.

Methotrexate — the most-used and best-studied second-line agent. Taken once weekly (with daily folic acid to reduce side effects). Requires periodic blood tests to monitor the liver and blood counts. Alcohol should be limited.
Azathioprine, leflunomide, mycophenolate — alternatives when methotrexate isn’t suitable or tolerated, each with their own monitoring.
Hydroxychloroquine — particularly useful for skin sarcoidosis and for high blood calcium; needs periodic eye exams.

Step 3 — Biologic therapy (anti-TNF)

For disease that does not respond to the medicines above — or for severe involvement of the skin, eyes, or nervous system — an intravenous biologic called infliximab (an anti-TNF antibody) is the option with the most evidence. Adalimumab is sometimes used as well. These are powerful and can bring stubborn sarcoidosis under control.

Before starting a biologic, screening is mandatory. Because anti-TNF drugs lower your defenses against certain infections, you will be tested for latent tuberculosis and hepatitis B/C first, and vaccinations are reviewed. Tell every provider you are on a biologic, and report fevers or infections promptly.

How the steps fit together

Think of it as: observe if you can → steroid if you must → add a steroid-sparing medicine early to get off the steroid → escalate to a biologic for refractory or severe disease. Many people never climb past the first or second rung. The aim throughout is the smallest amount of medicine that keeps your disease and symptoms controlled.

Reference doses, real-world costs & stop rules. There is no FDA-approved sarcoidosis-specific drug — the medicines below are used off-label, with doses drawn from each drug’s FDA label and from the ERS 2021 treatment guideline and WASOG guidance. These are reference ranges only; your own dose is set by your team.

Prednisone (steroid, first-line): commonly started around 20–40 mg/day and tapered to the lowest effective maintenance dose (often 5–10 mg/day) over roughly 6–12 months (ERS 2021 treatment guideline).
Methotrexate (steroid-sparing, most-used): about 10–15 mg once weekly (up to ~25 mg), taken with folic acid 5 mg weekly to reduce side effects (ERS 2021 / WASOG). Weekly, never daily.
Hydroxychloroquine (skin disease, high calcium): about 200–400 mg/day, with periodic eye exams (ERS 2021).
Nintedanib (Ofev, antifibrotic for progressive scarring): 150 mg twice daily (U.S. FDA label for progressive fibrosing interstitial lung disease).
Infliximab (biologic for refractory/severe disease): about 3–5 mg/kg by IV infusion at weeks 0, 2 and 6, then every 4–8 weeks (Baughman 2006 randomized trial).

What these cost (U.S., as of July 2026).

Prednisone and methotrexate are inexpensive generics. Cash prices run about $35 for a month of prednisone and about $29 for a month of oral methotrexate, and often drop to $10 to $13 with a free pharmacy discount coupon (GoodRx/SingleCare estimates, July 2026).
Nintedanib (Ofev) is a high-cost branded drug. Boehringer Ingelheim’s OPEN DOORS patient-support program offers copay help for commercially insured patients and free medication for eligible uninsured patients — 1-866-OPENDOOR (1-866-673-6366), ofev.com.
Infliximab and other infused biologics are covered through insurance with prior authorization; infusion-center specialty pharmacists and manufacturer patient-assistance programs can substantially reduce out-of-pocket cost — ask your infusion center to help you apply.

Stop and change rules your team watches (when to stop, hold, or step up):

Steroids: if you still need more than 10 mg/day of prednisone after about 6 months to stay controlled, guidelines advise adding a steroid-sparing medicine rather than continuing high-dose steroids (BTS 2021). Steroids are tapered, never stopped abruptly.
Methotrexate: blood tests are checked periodically; clinicians typically hold it and may discontinue if liver enzymes (AST/ALT) rise above about 3 times the normal limit (rheumatology drug-monitoring guidance), and it must be stopped before any possible pregnancy (FDA label — methotrexate causes miscarriage and birth defects).
Biologics (infliximab): stopped promptly for a serious infection; latent tuberculosis and hepatitis B/C must be excluded before starting (FDA Boxed Warning).

Ask your doctor: "Given the PREDMETH trial, could I start methotrexate instead of — or alongside a short course of — prednisone, to limit steroid side effects?"

Ask your doctor: "What is my exact prednisone taper schedule, and at what point would we add a steroid-sparing medicine or stop it?"

Dosing quick-reference for the medicines used in sarcoidosis

The table below gathers the reference dose ranges in one place. Every one of these drugs is used off-label for sarcoidosis (there is no FDA-approved sarcoidosis pill except repository corticotropin), so the doses come from each drug’s FDA label plus the ERS 2021 treatment guideline and WASOG guidance. These are reference ranges only — your own dose is set by your team.

Medicine	Typical starting / target dose (off-label)	How it is taken	Source
Prednisone (first-line steroid)	Induction about 20-40 mg once daily; taper to a maintenance dose of about 5-10 mg daily; higher (about 0.5 mg/kg/day) for cardiac or neurologic disease	By mouth, once daily; taper slowly	ERS 2021 treatment guideline; prednisone FDA label
Methotrexate (preferred steroid-sparing)	About 10-15 mg once weekly, up to about 25 mg weekly, taken with folic acid 5 mg weekly	Once weekly — never daily; by mouth or injection	ERS 2021 / WASOG; methotrexate FDA label
Hydroxychloroquine (skin disease, high calcium)	About 200-400 mg/day, generally kept at or below 5 mg/kg/day to protect the retina	By mouth, daily; annual eye exam	ERS 2021 guideline; AAO 2016 screening
Azathioprine (alternative)	About 2-3 mg/kg/day (a TPMT blood test is checked first)	By mouth, daily	ERS 2021; azathioprine FDA label
Leflunomide (alternative)	About 10-20 mg/day	By mouth, daily	ERS 2021; leflunomide FDA label
Mycophenolate (often used for neurosarcoidosis)	About 1000-1500 mg twice daily	By mouth, twice daily	WASOG; used off-label
Infliximab (anti-TNF biologic; refractory/severe)	About 3-5 mg/kg by IV infusion at weeks 0, 2 and 6, then every 4-8 weeks	IV infusion at an infusion center	Baughman 2006 randomized trial; infliximab FDA label
Adalimumab (alternative anti-TNF)	About 40 mg every 1-2 weeks (sometimes an 80 mg loading dose)	Under-the-skin injection	Judson 2008 trial; adalimumab FDA label
Nintedanib (Ofev; antifibrotic for scarring)	150 mg twice daily; reduced to 100 mg twice daily if not tolerated	By mouth with food, twice daily	INBUILD trial (NEJM 2019); Ofev FDA label
Repository corticotropin (H.P. Acthar Gel)	About 40-80 units by injection, roughly 1-3 times weekly (rarely used; very costly)	Under-the-skin or muscle injection	Acthar Gel FDA label (the only FDA-approved sarcoidosis drug)

Stop, hold, and change rules to keep in view: steroids gain a steroid-sparing partner if more than 10 mg/day is still needed after about 6 months (BTS 2021 guideline); methotrexate is held and your team may discontinue if liver enzymes rise above roughly 3 times normal, and it must be stopped before any pregnancy (FDA label); a biologic is stopped for any serious infection. Ask your team to write down your personal stop rules so you know exactly when to stop or change each medicine.

Ask your pulmonologist: "Which of these medicines fits my organ involvement, and what exact dose and monitoring schedule are you proposing for me?"

Ask your pharmacist: "Can you flag my methotrexate as a once-weekly medicine in your system so a daily-dosing error can never happen at the counter?"

What sarcoidosis treatment costs, and how to get help paying (U.S., as of July 2026)

Cost is one of the most practical things patients actually hit. The generics are inexpensive; the biologics and the antifibrotic are costly but almost always have a coverage path. Figures below are approximate U.S. cash prices or manufacturer list (WAC) prices as of July 2026 and vary widely by pharmacy, insurer, and region — use them to plan questions, not as a quote (GoodRx/SingleCare cash estimates and published WAC).

Medicine	Approx. U.S. price (July 2026)	How to lower it
Prednisone (generic)	About $4-$15 for a month (as low as $4 on some generic lists); roughly $50-$180 per year	GoodRx/SingleCare coupon; $4 generic programs
Methotrexate oral (generic)	About $25-$40 cash for a month, often $10-$13 with a discount coupon; roughly $120-$480 per year	GoodRx/SingleCare coupon; 90-day fills
Methotrexate auto-injector (branded)	About $300-$500 per month	Use oral tablets unless injection is needed; manufacturer copay card
Hydroxychloroquine (generic)	About $20-$40 per month	Coupon; 90-day fills
Azathioprine / leflunomide (generic)	About $15-$50 per month each	Coupon; generic programs
Mycophenolate (generic)	About $30-$70 per month	Coupon; 90-day fills
Folic acid (with methotrexate)	About $4 for a month	Over-the-counter; generic
Infliximab (originator/biosimilar, infused)	Originator about $1,000-$1,300 per 100 mg vial (roughly $4,000-$6,000 per infusion by body weight), plus an infusion facility fee of about $200-$500; biosimilars about $400-$700 per vial	Ask for a biosimilar; medical-benefit billing; manufacturer patient assistance
Adalimumab (brand/biosimilar, injected)	Brand about $6,900 per month; biosimilars about $550-$2,000 per month	Biosimilar switch; manufacturer copay card
Nintedanib (Ofev, branded)	About $12,000 per month (roughly $145,000 per year)	Boehringer Ingelheim OPEN DOORS: 1-866-673-6366, ofev.com
Repository corticotropin (Acthar Gel)	About $40,000 or more per vial — rarely justified given far cheaper options	Prefer standard immunosuppression; specialty prior authorization

Coverage paths that matter: generics are cheap enough to pay cash with a free coupon (often $10-$40 a month); infused biologics such as infliximab are usually billed under your medical benefit (for Medicare, Part B, which pays 80% after your Part B costs, leaving about a 20% coinsurance unless you have a supplement); injected and oral specialty drugs run through the pharmacy benefit with prior authorization. Since 2025 a Medicare Part D out-of-pocket cap (about $2,000 per year) limits what many patients pay for pharmacy drugs, and manufacturer patient-assistance programs can bring eligible patients’ out-of-pocket cost close to $0. A single infliximab infusion can be billed at roughly $4,000-$6,000 before insurance, while a month of generic prednisone plus methotrexate may total under $50 — a reminder to ask about biosimilars and assistance early.

Ask your pharmacist: "Can you run a GoodRx or SingleCare coupon on my generics, and tell me the cheapest cash price today?"

Ask your doctor: "Is a biosimilar infliximab an option for me, since it can cost a fraction of the originator?"

Ask your team: "Which patient-assistance program should I apply to, and can the infusion center’s specialty pharmacist help me file it?"

How the medicines work together (combinations and steroid-sparing “stacking”)

Sarcoidosis treatment is often a deliberate combination, not one drug at a time. The steroid-sparing strategy is itself a synergy: a steroid-sparing medicine such as methotrexate is started while prednisone is still on board so the two overlap, letting the steroid be tapered while control is maintained — the combined effect keeps disease quiet on a much lower steroid dose than either would manage comfortably alone. For refractory disease, adding a low-dose antimetabolite (methotrexate or azathioprine) alongside infliximab is a recognized combination that both improves response and reduces anti-drug antibodies, so the biologic keeps working longer. These stacking strategies are how specialists minimize steroid exposure while protecting organs; the amplified effect of the combination is the point, not simply “more drugs.”

Ask your doctor: "Are we combining a steroid-sparing medicine with my prednisone so I can taper the steroid faster?"

Monitoring blood tests while on these medicines

Most sarcoidosis medicines need routine blood tests so problems are caught early. Typical patterns, drawn from each drug’s FDA label and rheumatology drug-monitoring guidance:

Prednisone — blood sugar and blood pressure checks; bone-density (DXA) assessment for longer courses (per glucocorticoid-monitoring guidelines).
Methotrexate — a full blood count, liver panel, and kidney function at the start, then roughly every 8-12 weeks once stable (ERS 2021 guideline; methotrexate FDA label).
Azathioprine — a TPMT enzyme test before starting, then periodic blood counts and liver tests.
Hydroxychloroquine — a baseline eye exam and then annual retinal screening (per the 2016 ophthalmology screening guideline).
Infliximab / adalimumab — latent tuberculosis and hepatitis B/C testing before the first dose, then vigilance for infection at every visit (FDA Boxed Warning).
Nintedanib — periodic liver tests, with a dose reduction or pause if they rise (Ofev FDA label).

Ask your doctor: "What is my exact blood-test schedule for each medicine, and who will call me if a result is off?"

For caregivers — helping manage the medicines:

On prednisone: watch for mood swings, insomnia, increased appetite/weight, higher blood sugar (especially if diabetic), and stomach upset. Support bone health (calcium/vitamin D as advised — see the calcium caution below), and help keep eye-exam appointments (steroids can cause cataracts/glaucoma). Never stop steroids abruptly — they must be tapered.
On steroid-sparing medicines: help track the weekly methotrexate schedule (a common, dangerous error is taking it daily instead of weekly), keep up with monitoring blood tests, and have a reliable system for lab reminders.
On any immunosuppressant or biologic: be alert to infections — fever, productive cough, urinary symptoms, or skin infection deserve prompt attention. Keep vaccinations current as the team advises (generally avoiding live vaccines while immunosuppressed).

Sarcoidosis granulomas can convert vitamin D into its active form in an unregulated way, which can raise blood calcium and cause kidney stones or kidney injury. Because of this, people with sarcoidosis should be cautious about vitamin D and calcium supplements and high-calcium regimens unless specifically guided by their doctor. If your calcium is high, your team may recommend hydroxychloroquine or other steps, avoiding excess sun and supplements, and staying well hydrated. Always check before starting any vitamin D — what is healthy advice for the general public can be the wrong move in sarcoidosis.

If I need treatment, would you start with prednisone, a steroid-sparing medicine, or both — and why?
What dose of prednisone, and what is the taper plan? How will we limit side effects?
When would we add methotrexate (or another steroid-sparing medicine), and what monitoring does it need?
What would make you consider a biologic like infliximab, and what screening comes first?
Given the PREDMETH results, is starting with methotrexate a reasonable option for me?
What should I do about calcium and vitamin D — is it safe for me to take supplements?
Which side effects should I report right away versus mention at the next visit?

Heart, Nerve, Eye, Skin & Liver Involvement

Sarcoidosis can affect organs beyond the lungs. Some of these are mild; a few are serious and benefit from being caught early. This section walks through the most important ones — and what to watch for.

Heart (cardiac sarcoidosis) — uncommon but high-stakes

Granulomas in the heart can disturb its electrical wiring (causing abnormal rhythms or conduction block) or weaken the heart muscle. Cardiac sarcoidosis is one of the leading causes of serious outcomes in this disease, including sudden cardiac problems — which is exactly why doctors now look for it proactively.

The numbers have improved because detection and treatment have improved. A baseline ECG screens everyone. If heart involvement is suspected, specialized imaging — cardiac MRI and FDG-PET scanning — can find and characterize it. Treatment combines immunosuppression (to calm the inflammation) with cardiology care, which may include rhythm medicines and, when the risk of dangerous rhythms is high, an implantable defibrillator (ICD). A 2024 American Heart Association scientific statement reflects how much this field has matured.

Report immediately: palpitations, fainting or near-fainting, or new unexplained breathlessness. These are the symptoms that should never be brushed off.

Why the heart is a life-or-death issue in sarcoidosis. Granulomas in the heart muscle can interrupt the heart’s electrical wiring (causing heart block) or trigger dangerous fast rhythms from the lower chambers (ventricular arrhythmia). Both can cause sudden cardiac death — and cardiac involvement can be the first sign of sarcoidosis, sometimes in someone who felt well. That is why a new heart block, a serious arrhythmia, fainting, or an unexplained weakening of the heart muscle in a person with (or at risk of) sarcoidosis should trigger a cardiac MRI and/or FDG-PET and a conversation about an implantable defibrillator (ICD). Do not let this one be missed.

Ask your cardiologist: "Given my sarcoidosis, do I need a cardiac MRI or FDG-PET, and does my arrhythmia risk warrant discussing an implantable defibrillator (ICD)?"

Nervous system (neurosarcoidosis)

This can affect the cranial nerves (a common example is facial weakness), the brain and its lining, the pituitary gland, or the spinal cord. Because nerve tissue is delicate, neurosarcoidosis is usually treated aggressively — typically steroids combined with a stronger steroid-sparing medicine or a biologic (often methotrexate or infliximab) — to protect function.

Ask your neurologist: "Is my neurosarcoidosis being treated aggressively enough — should we add infliximab or a stronger steroid-sparing medicine to protect nerve function?"

Eyes (ocular sarcoidosis)

Inflammation inside the eye (uveitis) is common and can occasionally be the first sign of the disease. Untreated, it can threaten sight. The good news is that it responds well to prompt treatment — which is why a baseline eye exam is recommended even without eye symptoms, and why any eye redness, pain, light sensitivity, floaters, or vision change deserves a quick evaluation.

Ask your ophthalmologist: "Do I have any uveitis, how often should my eyes be checked, and which eye symptoms mean I should be seen the same day?"

Skin (cutaneous sarcoidosis)

Skin disease ranges from the tender shin bumps of erythema nodosum (which usually heals) to lupus pernio, a persistent purplish thickening of the skin on the nose, cheeks, and ears that can be disfiguring and is often a marker of more chronic disease. Skin sarcoidosis is treated based on severity, from topical and antimalarial (hydroxychloroquine) therapy up to biologics for stubborn cases.

Ask your doctor: "Is my skin sarcoidosis (especially lupus pernio) a sign of more chronic disease, and would hydroxychloroquine or a biologic help?"

Liver, spleen, kidneys, and blood counts

These are often silent. Liver and spleen involvement may show up only on blood tests or imaging and frequently needs no specific treatment. Kidney issues are often tied to the high-calcium problem described earlier. Your routine blood work is partly there to keep an eye on all of this.

For caregivers — the heart is where vigilance matters most: Learn the three cardiac red flags by heart: palpitations, fainting/near-fainting, and new unexplained breathlessness. If your person faints or has a prolonged racing heartbeat, treat it as urgent. Also help them keep eye exams (for uveitis) and attend cardiology, neurology, and other specialist visits — multidisciplinary care is one of the biggest advantages in managing multi-organ sarcoidosis. Keeping a simple symptom log across organs helps the whole team spot patterns.

Have we checked my heart? If something looks off on my ECG, would I have a cardiac MRI or PET scan?
What heart symptoms should send me to urgent care or the emergency room?
Do I have any eye or nervous-system involvement, and how often should those be re-checked?
If my skin is involved, what are my options — and is lupus pernio a sign my disease may be more chronic?
Are my liver, kidney, and blood tests normal, and what would prompt action if they changed?
Which specialists should be part of my team, and who coordinates them?

Fatigue & Everyday Symptoms

If you remember one thing from this section: fatigue is the most common and most disabling symptom of sarcoidosis — and it is real. It can persist even when scans and breathing tests look stable, which sometimes leads to it being underestimated by others. You are not imagining it, and it deserves attention in its own right.

Why am I so tired? Sarcoidosis fatigue has several overlapping causes: the inflammatory disease itself, the effects of medications (steroids can disrupt sleep; some steroid-sparing agents cause fatigue or nausea), poor sleep, depression or anxiety that often accompany chronic illness, and sometimes a related nerve problem called small-fiber neuropathy (causing burning, tingling, or pain). Untangling the causes is the first step to addressing them.

What actually helps

Pacing and energy budgeting — planning demanding activities for your best hours and building in rest, rather than pushing to exhaustion.
Graded exercise and pulmonary rehabilitation — counterintuitively, supervised, gradually increasing activity is one of the better-supported approaches for sarcoidosis fatigue and breathlessness.
Sleep hygiene and screening for sleep apnea — which is common and very treatable.
Treating depression/anxiety — not because the fatigue is “in your head,” but because mood and energy are biologically linked and treating one helps the other.
Reviewing medications — sometimes adjusting a steroid dose or timing, or a steroid-sparing agent, makes a real difference.
Addressing small-fiber neuropathy — if burning/tingling is part of the picture, specific treatments exist.

Small-fiber neuropathy

Some people with sarcoidosis develop damage to the smallest nerve fibers, causing burning, tingling, numbness, or pain — and contributing to fatigue. Notably, this can occur even when standard tests look normal, so it can be missed. If this sounds like you, ask specifically about it; there are ways to evaluate and manage it.

Ask your doctor: "Could my fatigue have a treatable driver — small-fiber neuropathy, sleep apnea, thyroid problems, anemia, or depression — and can we test for each?"

For caregivers: Profound fatigue is hard for others to see and easy to underestimate. Believe it, and help your person pace rather than push — protecting energy for what matters most to them. Practical support (sharing chores on bad days, helping plan around peak-energy windows, encouraging gentle regular activity rather than boom-and-bust cycles) is genuinely therapeutic. And watch for low mood or withdrawal; depression is common in chronic illness and very treatable.

Could my fatigue be from the disease, my medications, poor sleep, mood, or a nerve issue — and how do we sort that out?
Would pulmonary rehabilitation or a graded exercise program help me?
Should I be screened for sleep apnea or for small-fiber neuropathy?
Are any of my medicines making the fatigue worse, and can we adjust them?
Can you connect me with support for the mental and emotional side of living with this?

Advanced Lung Disease & Living Well

Most people never reach advanced disease. But for the minority whose lungs scar over time, or who develop high blood pressure in the lung arteries, there are real, effective ways to slow decline and maintain quality of life.

Pulmonary fibrosis (lung scarring)

In a subset of people, chronic inflammation gives way to fibrosis — scarring that, unlike inflammation, does not reverse with immune-suppressing medicines. Recognizing when disease has shifted from “active inflammation” (which immunosuppression can help) to “scarring” (which it cannot) is an important judgment your team makes, sometimes with the help of imaging and PET scanning.

An antifibrotic option exists. For people with a progressive fibrosing pattern, a medicine called nintedanib (Ofev) can slow the decline in lung function. It was studied in a large trial (INBUILD) across many fibrotic lung diseases, including fibrotic sarcoidosis. It does not reverse scarring, and it has side effects (commonly diarrhea), but for the right person it is a meaningful tool.

Ask your pulmonologist: "Is my lung disease now scarring (fibrosis) rather than active inflammation, and if so, am I a candidate for the antifibrotic nintedanib?"

Sarcoidosis-associated pulmonary hypertension (SAPH)

Some people develop high pressure in the blood vessels of the lungs, which can cause breathlessness out of proportion to other findings. This is evaluated by specialists (often with an echocardiogram and, when needed, a right-heart catheterization) and managed in specialized centers. Medicines used for other forms of pulmonary hypertension are sometimes tried, but the evidence in sarcoidosis is still limited, so this is best handled by an expert team.

Oxygen, rehabilitation, and transplant

Supplemental oxygen when blood oxygen runs low, to support activity and protect the heart.
Pulmonary rehabilitation — structured exercise and education that improves stamina, breathlessness, and quality of life.
Lung transplantation for carefully selected people with end-stage disease — an option that can extend and improve life when other measures are exhausted.

Living well across the whole journey

Bone protection if you are on steroids (your team will advise on monitoring and protective steps).
Vaccinations kept current per your team (important on immunosuppression; generally avoiding live vaccines while immunosuppressed).
Lung health — avoid smoking and secondhand smoke, and ask about indoor air quality and occupational exposures.
Mental health — an unpredictable, invisible illness takes a psychological toll; support is part of good care, not a luxury.

Can I get pregnant?

Many people with sarcoidosis have healthy pregnancies, and for some, disease activity even quiets during pregnancy. However, some medications used in sarcoidosis are not safe in pregnancy (methotrexate, leflunomide, and mycophenolate must be stopped and avoided), while others can be continued under guidance. If you are considering pregnancy, plan ahead with your team so your regimen can be adjusted safely before conception, and so any heart or lung involvement is assessed.

Ask your doctor: "If I want to become pregnant, which of my medicines must be stopped first — and how long before conception?"

For caregivers: In advanced disease, your role often expands — coordinating oxygen, helping with rehabilitation, attending transplant evaluations, and providing steady emotional support through uncertainty. Take care of your own wellbeing too; caregiver burnout is real, and you are most helpful when you are also supported. Ask the care team about caregiver resources and respite options.

Is my lung disease mostly active inflammation (treatable with immunosuppression) or scarring (fibrosis)?
Am I a candidate for an antifibrotic medicine like nintedanib?
Should I be evaluated for pulmonary hypertension, and at a specialized center?
Would oxygen or pulmonary rehabilitation help me now?
If my disease became end-stage, when would we talk about lung transplant evaluation?
If I want to become pregnant, how should we adjust my medications and timing?
What bone protection, vaccinations, and lifestyle steps do you recommend for me?

Clinical Trials & New Treatments — an Honest Look

Sarcoidosis research is active, and clinical trials are a reasonable thing to ask about. But you deserve a clear-eyed picture rather than hype — especially because the two most advanced recent drug trials did not succeed. Here is where things genuinely stand.

The big recent news is sobering but honest. Two targeted medicines reached late-stage trials and were widely hoped to become the first new sarcoidosis-specific therapies in decades. Both missed their main goals:

Efzofitimod (the EFZO-FIT phase 3 trial, NCT05415137) did not meet its primary endpoint of reducing steroid use, reported in September 2025. Some secondary measures (quality of life, complete steroid withdrawal, fatigue) looked favorable at the higher dose. After an FDA meeting in April 2026, the company announced in May 2026 that it plans to run a new phase 3 trial — this time in people with chronic, symptomatic pulmonary sarcoidosis who have stiff (restrictive) lungs, using lung function (forced vital capacity, FVC) as the main goal. So the drug is still being developed, but it remains investigational, is not approved or proven, and any possible approval is still years away.
Namilumab (the RESOLVE-Lung phase 2 trial, NCT05314517) also failed its primary endpoint, reported in December 2024, and its development for sarcoidosis was discontinued.

Why share disappointing results? Because honesty protects you. Anyone promising a “breakthrough cure” based on these drugs is ahead of the evidence.

What did move care forward recently

PREDMETH (NCT04314193, NEJM 2025) — showed methotrexate can be a reasonable first-line alternative to prednisone for lung sarcoidosis, with fewer lingering side effects. This is a real, practice-relevant advance.
Better heart care — a 2024 American Heart Association scientific statement consolidated how to detect and manage cardiac sarcoidosis.

What is still being studied

JAK inhibitors (such as tofacitinib) — oral medicines targeting an inflammatory pathway active in sarcoidosis. Early studies and many case reports show promise, especially for stubborn skin disease; they are used off-label in some refractory cases and are being studied further. Not yet approved for sarcoidosis.
Other agents — an anti-TNF antibody (XTMAB-16) completed enrollment in an early trial; agents targeting other inflammatory signals have been tested with mixed results; inhaled treprostinil is studied for sarcoidosis-associated pulmonary hypertension. These remain investigational.
Better measurement tools — research into PET imaging and biomarkers aims to better separate active inflammation from old scarring, to guide who needs treatment.
Fatigue and quality of life — studies are testing exercise programs and other approaches because fatigue matters so much day to day.

Specific trials you can look up (as of July 2026)

These are real, registered studies — search the identifier on ClinicalTrials.gov. Being registered is not an endorsement; ask your specialist whether any fit you.

OATD-01 — an oral drug (a chitinase inhibitor) being tested in active pulmonary sarcoidosis (phase 2, recruiting): NCT06205121.
XTMAB-16 — a new anti-TNF antibody in pulmonary sarcoidosis (phase 1/2, recruiting): NCT05890729.
Hydroxychloroquine as a steroid-sparing option for extrapulmonary sarcoidosis (phase 4, recruiting): NCT05841758.
Cardiac sarcoidosis imaging — a study of PET/MRI to predict outcomes (recruiting): NCT05954507; plus a long-running cardiac sarcoidosis cohort, NCT01477359.
Fatigue and rehabilitation — yoga versus standard physiotherapy for sarcoidosis (recruiting): NCT06848608.
Steroid tapering — comparing prednisolone taper schedules (recruiting): NCT07498842.
Tofacitinib (a JAK inhibitor) for skin sarcoidosis — a completed open-label study: NCT03910543.

Ask your doctor: "Are any registered sarcoidosis trials — for example NCT06205121, or one matching my organ involvement — a reasonable option for me right now?"

How to find and evaluate a trial

Search ClinicalTrials.gov (the official U.S. registry) for “sarcoidosis” plus your organ or city.
Ask your sarcoidosis specialist or a center of excellence — many trials run only at specialized centers.
The Foundation for Sarcoidosis Research maintains trial information and patient resources.
For any trial, ask: What is being tested and why? What are the risks and the time commitment? Could I get a placebo? Who covers costs? What happens when the trial ends?

Honesty about what does not work is as important as knowing what does:

Efzofitimod and namilumab — as above, both missed their primary endpoints in recent trials. Treat “miracle new sarcoidosis drug” claims with skepticism.
Etanercept — another anti-TNF drug — performed poorly for sarcoidosis in studies, unlike infliximab. Not all drugs in a class work the same way.
Antibiotic “CLEAR”-type regimens — combination antimicrobial protocols have been explored based on the theory that microbes trigger sarcoidosis, but they are not established standard care; evidence is limited.
Supplements and “immune-boosting” protocols — there is no supplement proven to treat sarcoidosis, and some (especially vitamin D and calcium) can be actively harmful by worsening high calcium. Always clear supplements with your team.
Cannabis/CBD as a disease treatment — may help some symptoms for some people, but there is no evidence it treats the underlying disease; discuss interactions and risks.

None of this is a substitute for evaluation and care by a qualified clinician.

Are there clinical trials that fit my type of sarcoidosis, and would you recommend one for me?
What do you make of the efzofitimod and namilumab trial results — do they change anything for me?
Is an off-label JAK inhibitor ever appropriate for my situation (for example, stubborn skin disease)?
How do we tell whether my lung changes are still “active” (treatable) or scarring?
I read about a treatment online — is there real evidence behind it, or is it a claim to be cautious about?

Specialty Centers, Access & Support

Multidisciplinary care — pulmonology working alongside cardiology, neurology, ophthalmology, rheumatology, and others — is one of the biggest advantages in managing a multi-organ disease like sarcoidosis. Below are resources, starting close to home for readers in the Mountain West.

Mountain West & Utah

University of Utah Health (Salt Lake City) — multidisciplinary sarcoidosis-relevant care across pulmonary/interstitial lung disease, rheumatology, cardiology (cardiac-sarcoidosis evaluation with MRI/PET and electrophysiology), neurology, and the John A. Moran Eye Center for uveitis; infliximab infusion services and clinical trials. Main line: 801-581-2121.
Intermountain Health (Wasatch Front and across Utah) — pulmonology and multidisciplinary clinics for diagnosis, pulmonary function testing, immunosuppression management, and infusion services. Find a provider: 801-442-5000 (Intermountain Medical Center, Murray).
George E. Wahlen VA Medical Center (Salt Lake City) — pulmonary and multisystem sarcoidosis care for veterans. Main line: 801-582-1565.
Infusion centers & specialty pharmacies (University of Utah, Intermountain) — administer infliximab and help coordinate specialty-drug approvals and patient-assistance programs.

U.S. national centers of excellence (illustrative)

Before traveling, use these scripts. Ask your doctor: "Should I be seen at a specialized sarcoidosis or ILD center, and can you refer me?" Ask your team: "If I need a biologic or antifibrotic, who handles the insurance approval and what will my share of the cost be?" Several academic centers have dedicated sarcoidosis or interstitial lung disease programs with deep experience in cardiac and neurologic disease. Examples frequently cited include the Cleveland Clinic, Johns Hopkins, University of Cincinnati, National Jewish Health (Denver), Mount Sinai (New York), and Mayo Clinic. The Foundation for Sarcoidosis Research can help you locate specialists; ask your insurer about in-network options and any referral requirements before traveling.

Veterans

Sarcoidosis is recognized within the VA system, and veterans should ask about service connection if their diagnosis may relate to military exposures (for some veterans, sarcoidosis has been considered presumptively connected to certain service circumstances — eligibility rules change, so ask a Veterans Service Officer). The Salt Lake City VA and the broader VA pulmonary network can coordinate care.

Canada

Care is delivered through provincial health systems and academic respirology programs (for example, in Toronto, Montreal, and Vancouver). Biologics and antifibrotics may require special authorization through provincial drug plans; ask your respirologist about coverage pathways and timelines.

International

Notable specialized centers include St. Antonius Hospital (Nieuwegein, Netherlands), Royal Brompton Hospital (London, UK), and academic centers across France, Germany, Italy, Spain, and Japan (the latter with particular cardiac-sarcoidosis expertise). The World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) is a useful starting point.

Education, peer support & assistance

Foundation for Sarcoidosis Research (FSR) — stopsarcoidosis.org — education, peer-support communities, trial information, and financial-assistance and fatigue resources.
American Lung Association — lung.org — general lung-health education and support.
ClinicalTrials.gov — the official registry of clinical trials.

For caregivers: If your person’s care is scattered across specialists, ask whether a single sarcoidosis or ILD clinic can coordinate — it reduces conflicting advice and dropped balls. Keep a one-page summary (diagnosis, organs involved, current medicines and doses, allergies, key contacts) to bring to every visit and any ER trip. For biologics and antifibrotics, specialty pharmacies and manufacturer patient-assistance programs can substantially reduce cost — ask the infusion center or pharmacist to help you apply.

Which treatments are available — and approved — varies by country:

Prednisone and other steroids — available essentially everywhere; the universal first-line when treatment is needed.
Methotrexate, azathioprine, leflunomide, mycophenolate, hydroxychloroquine — widely available, but mostly used off-label for sarcoidosis (approved for other conditions). This is normal and evidence-based, even without a sarcoidosis-specific label.
Infliximab / adalimumab (biologics) — available in most developed health systems, but used off-label for sarcoidosis and often requiring prior authorization. Access and cost vary widely.
Nintedanib (Ofev) — approved (US FDA, EMA in Europe, others) for progressive fibrosing interstitial lung disease, which can include fibrotic sarcoidosis — though coverage rules differ by country and payer.
Repository corticotropin (H.P. Acthar Gel) — a U.S.-specific FDA-approved option for symptomatic sarcoidosis; rarely used elsewhere, expensive, and with limited modern trial evidence.
Efzofitimod — not approved anywhere; investigational. It missed its main phase 3 goal in 2025; a redesigned phase 3 (FVC endpoint, restrictive disease) was announced in May 2026.
Regional emphasis — in countries with high tuberculosis or endemic fungal infection (much of South Asia, parts of Africa, Latin America), ruling out infection before diagnosing sarcoidosis is an even more central step. Japan has historically led in cardiac-sarcoidosis recognition.

Should I be seen at a specialized sarcoidosis or ILD center, and can you refer me?
Who coordinates my care across specialists?
If I need a biologic or antifibrotic, how do we handle insurance approval and cost?
Are there patient-assistance programs I qualify for?
Can you connect me with a peer-support community or the Foundation for Sarcoidosis Research?

Glossary & Key Sources

Granuloma — a small cluster of immune cells; the building block of sarcoidosis.
Noncaseating granuloma — a granuloma without a dead, cheese-like center; the type seen in sarcoidosis (helps distinguish it from TB).
Diagnosis of exclusion — a diagnosis made only after ruling out look-alike conditions.
Löfgren syndrome — an acute form (shin bumps + chest node enlargement + arthritis/fever) with a generally good outlook.
Scadding stage — a chest X-ray pattern (0–IV), not a severity score.
EBUS-TBNA — a minimally invasive scope-and-needle procedure to biopsy chest lymph nodes.
Glucocorticoid / prednisone — a steroid anti-inflammatory medicine; usual first treatment.
Steroid-sparing agent — a medicine (e.g., methotrexate) used to control disease while lowering steroid dose.
Biologic / anti-TNF — a targeted antibody medicine (e.g., infliximab) for refractory/severe disease.
Uveitis — inflammation inside the eye; can threaten vision.
Lupus pernio — a persistent purplish facial skin form of sarcoidosis.
Cardiac sarcoidosis — heart involvement; can cause dangerous rhythm problems.
Neurosarcoidosis — nervous-system involvement.
Fibrosis — scarring; does not reverse with immune-suppressing medicines.
Antifibrotic (nintedanib) — a medicine that can slow progressive lung scarring.
SAPH — sarcoidosis-associated pulmonary hypertension (high pressure in lung arteries).
Small-fiber neuropathy — damage to the smallest nerves causing burning/tingling and fatigue.
Serum ACE — a blood test sometimes ordered in sarcoidosis but not reliable for diagnosis or tracking.

ATS 2020 Diagnosis & Detection of Sarcoidosis (official ATS clinical practice guideline). Crouser ED, et al. Am J Respir Crit Care Med 2020;201(8):e26–e51.
ERS 2021 Clinical Practice Guidelines on Treatment of Sarcoidosis. Baughman RP, Valeyre D, Korsten P, et al. Eur Respir J 2021;58:2004079.
PREDMETH trial (methotrexate vs prednisone first-line). Kahlmann V, et al. N Engl J Med 2025;393(3):231–242. ClinicalTrials.gov NCT04314193.
Infliximab in pulmonary sarcoidosis (randomized trial). Baughman RP, et al. Am J Respir Crit Care Med 2006;174:795–802.
Nintedanib in progressive fibrosing ILD (INBUILD). Flaherty KR, et al. N Engl J Med 2019;381:1718–1727. NCT02999178.
HRS 2014 expert consensus on cardiac sarcoidosis. Birnie DH, et al. Heart Rhythm 2014;11:1305–1323; and the 2024 AHA Scientific Statement on cardiac sarcoidosis (Circulation).
Efzofitimod EFZO-FIT phase 3 topline results (missed primary endpoint), aTyr Pharma, September 2025; FDA Type C meeting and new phase 3 (FVC endpoint) announced May 2026. NCT05415137.
Namilumab RESOLVE-Lung phase 2 topline results (missed primary endpoint), Kinevant/Roivant, December 2024. NCT05314517.
BTS 2021 Clinical Statement on pulmonary sarcoidosis. Thillai M, et al. Thorax 2021;76:4–20 (the >10 mg/day beyond 6 months steroid-sparing threshold).
Tofacitinib in cutaneous sarcoidosis. Damsky W, et al. N Engl J Med 2018;379:2540–2546; follow-up open-label trial NCT03910543.
Hydroxychloroquine retinopathy screening guideline (American Academy of Ophthalmology, 2016 revision) — basis for the 5 mg/kg/day ceiling and annual eye exam.
ClinicalTrials.gov records verified July 2026: NCT06205121 (OATD-01 trial), NCT05890729 (XTMAB-16 trial), NCT05841758, NCT05954507, NCT01477359, NCT06848608, NCT07498842.
Foundation for Sarcoidosis Research (stopsarcoidosis.org) and American Lung Association (lung.org).

Important. This guide is educational and does not replace personalized medical advice. Sarcoidosis is highly variable, evidence is still evolving, and decisions should be made with your own care team, who know your full situation.